Retraction to: British Journal of Cancer (2011) 104, 68–74. doi: 10.1038/sj.bjc.6605972
After a thorough review, the corresponding author, Dr Antonio Gualberto, has concluded that the key results reported in this manuscript are incorrect and cannot be reproduced. As there are no remaining samples that would allow a new analysis, he has therefore recommended the retraction of the manuscript to the Editor-in-Chief of BJC.
The co-authors have been informed of this decision.
Dr Gualberto sincerely apologises for any inconvenience this may have caused the readers of the BJC.
Change history
24 January 2013
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Additional information
The online version of the original article can be found at 10.1038/sj.bjc.6605972
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Gualberto, A., Hixon, M., Karp, D. et al. Retraction Note: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 107, 2024 (2012). https://doi.org/10.1038/bjc.2012.497
Published:
Issue Date:
DOI: https://doi.org/10.1038/bjc.2012.497
This article is cited by
-
Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial
Cancer Chemotherapy and Pharmacology (2014)
